NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals (SUPN) Stock Rebounds As Revenue Growth Meets Profit Crunch
Supernus Pharmaceuticals stock climbed about 3% to roughly US$46, even as the company reported another quarterly loss. The headline this quarter is not the revenue line, which reached about US$219 million. The real story is the sharp hit to profitability, with basic earnings per share swinging to a loss of about US$1.01 and net income showing a loss of roughly US$58 million.
For investors, today’s modest bounce comes against a backdrop of pressure on margins and a trailing twelve month loss...